Why the study?
Human beta-cardiac myosin is an established therapeutic target for heart muscle diseases, but the potential of targeting other myosin family members across diseases remains to be fully explored.
Key points are not available for this paper at this time.
Design
Review
β-cardiac myosin is a viable drug target in heart muscle diseases; extends myosin modulation as a therapeutic strategy to other isoforms and conditions.
Myosins are among the most fascinating enzymes in biology. As extremely allosteric chemomechanical molecular machines, myosins are involved in myriad pivotal cellular functions and are frequently sites of mutations leading to disease phenotypes. Human β-cardiac myosin has proved to be an excellent target for small-molecule therapeutics for heart muscle diseases, and, as we describe here, other myosin family members are likely to be potentially unique targets for treating other diseases as well. The first part of this review focuses on how myosins convert the chemical energy of ATP hydrolysis into mechanical movement, followed by a description of existing therapeutic approaches to target human β-cardiac myosin. The next section focuses on the possibility of targeting nonmuscle members of the human myosin family for several diseases. We end the review by describing the roles of myosin in parasites and the therapeutic potential of targeting them to block parasitic invasion of their hosts.
No takes yet. Share an insight, caveat, or question.
Trivedi et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: